argenx initiates Phase II trial of ARGX-113 to treat pemphigus vulgaris
Belgium-based biotechnology firm argenx has initiated a Phase II clinical trial of its investigational agent, ARGX-113, to treat patients with pemphigus vulgaris (PV).
We report a case of treatment‐resistant Hailey–Hailey disease having failed topical and oral steroids, prophylactic aciclovir and doxycycline, and systemic therapies including dapsone, acitretin and ciclosporin. Low‐dose naltrexone 4·5 mg once daily was commenced following an incidental benefit in this patient's similarly affected sister. The clinical and psychological response to date has been considerable.
Conclusion: Dermatologists need to be aware of the detrimental effects of high-dose intravenous pulsed glucocorticoids on bone mineral density and assessment of this parameter should be done before the initiation of therapy and also at regular intervals thereafter. During follow up, either the lumbar spine or the head of radius can be used to assess the osteopenic effect of intravenous pulse steroids, whereas the lumbar spine is a better site for this evaluation in patients on oral steroids.
This population-based cross-sectional study estimates the association between pemphigus and 4 neurologic conditions using one of the largest cohorts of patients with pemphigus.
This cross-sectional study estimates the association between pemphigus and a wide range of nonhematologic malignancies by examining a large cohort of patients with pemphigus.
Roche announced today that the US Food and Drug Administration (FDA) has accepted the company ’s Supplemental Biologics License Application (sBLA) and granted Priority Review for the use of MabThera/Rituxan® (Rituximab) for the treatment of pemphigus vulgaris (PV), a rare, life-threatening condition characterized by progressive painful blistering of the skin and mucous membranes.
Several European countries recently developed international diagnostic and management guidelines for pemphigus, which have been instrumental in the standardization of pemphigus management,
Recent evidence indicates that autoimmunity may contribute to the pathogenesis of chronic obstructive pulmonary disease (COPD). COPD was observed at higher frequency in patients with several autoimmune diseases. The association between pemphigus and COPD has not been evaluated in the past.
Rituximab (RTX) is an effective therapy for patients with pemphigus. However it does not prevent relapse.